Skip to main content

Table 1 Comparison of demographic and clinical characteristics between survivors and non-survivors

From: Subclinical acute kidney injury is associated with adverse outcomes in critically ill neonates and children

  Survivors, n = 462 Non-survivors, n = 48 P value
Age, months 1.37 [0.33–16.0] 0.97 [0.33–13.5] 0.540
Age group, n    
 ≤ 28 days, n = 239 215 (46.5) 24 (50.0) 0.893
 ≤ 1 year, n = 132 120 (26.0) 12 (25.0)
 > 1 year, n = 139 127 (27.5) 12 (25.0)
Body weight, kg 4.2 [2.5–11.0] 2.9 [1.5–10.0] 0.035
Male, n 277 (60.0) 27 (56.3) 0.645
Illness severitya, score 6 [3–9] 10 [6–14] <0.001
Diagnosis on ICU admission
 Respiratory diseases, n 176 (38.1) 10 (20.8) 0.054
 Neurologic diseases, n 59 (12.8) 1 (2.1)
 Preterm/LBW, n 37 (8.0) 5 (10.4)
 Sepsis, n 45 (9.7) 11 (22.9)
 Poison/trauma/accident, n 34 (7.4) 5 (10.4)
 Cardiologic diseases, n 20 (4.3) 1 (2.1)
 Gastroenterologic, n 19 (4.1) 0 (0)
 Hematologic diseases, n 17 (3.7) 6 (12.5)
MVb, n 127 (27.5) 35 (72.9) <0.001
MV duration, days 0 [0–0.84] 2.23 [0–6.86] <0.001
MV duration ≥ 48 hours, n 89 (19.3) 24 (50.0) <0.001
AKIc, n 63 (13.6) 16 (33.3) 0.002
 AKI stage 1, n 36 (7.8) 7 (14.6) <0.001
 AKI stage 2, n 19 (4.1) 5 (10.4)
 AKI stage 3, n 8 (1.7) 4 (8.3)
Sepsisb, n 58 (9.7) 15 (22.9) 0.001
Shock/DICb, n 61 (13.2) 13 (27.1) 0.013
MODSb, n 65 (14.1) 14 (29.2) 0.009
Furosemideb, n 126 (27.3) 24 (50.0) 0.002
Steroidb, n 150 (32.5) 21 (43.8) 0.147
Antibioticsb, n 418 (90.5) 46 (95.8) 0.294
Vancomycinb, n 35 (7.6) 7 (14.6) 0.099
Mannitolb, n 115 (24.9) 16 (33.3) 0.225
Inotropeb, n 60 (13.0) 10 (20.8) 0.182
Hemofiltrationb, n 15 (3.2) 3 (6.3) 0.235
Initial uCysC, ng/mg uCr 311.82 [122.22–975.34] 1587.39 [583.19–8749.16] <0.001
Peak uCysC, ng/mg uCr 426.49 [165.23–1607.62] 7026.73 [1285.25–33879.56] <0.001
  1. Values are median [interquartile range] or number (percentage)
  2. AKI acute kidney injury, DIC disseminated intravascular coagulation, ICU intensive care unit, LBW low birth weight, MODS multi-organ dysfunction syndrome, MV mechanical ventilation, uCysC urinary cystatin C, uCr urinary creatinine
  3. aIllness severity was assessed by the score for neonatal acute physiology in critically ill neonates and the pediatric risk of mortality III score in critically ill children
  4. bAdministered or developed during ICU stay
  5. cDeveloped during the first week after ICU admission